Skip to content

May 1, 2026

Home
Signal News
Biopharma Brief
Week in Review
Contact

Light/Dark Button

Search for:

Home
Commercial
Eli Lilly lifts 2026 revenue guidance as Q1 marks dominant opening

Commercial

Eli Lilly lifts 2026 revenue guidance as Q1 marks dominant opening

Pharmaceutical Technology

Sales for Lilly blew past expectations in the quarter as demand for weight loss treatments showed no signs of abating.

Read full story

pharminent May 1, 2026 (Last updated: May 1, 2026)

Pharmaceutical Technology

Sales for Lilly blew past expectations in the quarter as demand for weight loss treatments showed no signs of abating.

Read full story

Post navigation

Previous: BMS brings the buzz around late-stage readouts amid a so-so Q1

Next: LEO Pharma to acquire gene therapy company Replay

Related Stories

Commercial

Lilly posts another ‘blowout quarter’ as focus turns to Foundayo launch

pharminent April 30, 2026

Commercial

Lilly clocks 56% revenue increase in Q1 but declining prices stunt growth

pharminent April 30, 2026

Commercial

Regeneron Q1 2026 net income falls 10% to $727m

pharminent April 30, 2026

You May Have Missed

Manufacturing

Novartis unveils North Carolina API plant as final piece of $23B US expansion

pharminent May 1, 2026

Pipeline

Amgen positions MariTide as potential ‘best monthly’ obesity drug

pharminent May 1, 2026

Regulatory

FDA’s ODAC delivers one loss, one win for AstraZeneca

pharminent May 1, 2026

Regulatory

Axsome receives FDA approval for Auvelity to treat Alzheimer’s agitation

pharminent May 1, 2026

Copyright © 2026 All rights reserved. | ReviewNews by AF themes.